Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that subgroup analyses of Parkinson’s disease patients taking amantadine immediate release (IR) who ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE